查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1611289

罕见疾病诊断市场：按组成部分、技术、疾病类型和最终用途 - 2025-2030 年全球预测

Rare Disease Diagnostics Market by Component (Consumable & Assay Kit, Diagnostic Instrument), Technology (Array Technology, Next Generation Sequencing, Sanger Sequencing), Disease Type, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，罕见疾病诊断市场价值为26.8亿美元，预计到2024年将达到31.2亿美元，复合年增长率为17.36%，预计到2030年将达到82.3亿美元。

罕见疾病诊断市场的特点是它在识别和管理影响一小部分人口的疾病方面发挥着重要作用。该细分市场需要先进的创新来提高诊断过程的准确性和及时性。早期疗育和个人化治疗计划的潜力凸显了对增强诊断的需求，这些计划可以显着改善患者的治疗结果。应用包括基因检测、生物标记检测和先进的诊断影像技术，最终用途包括医院、诊断实验室和研究机构。推动该市场成长的关键因素包括人们对罕见疾病的认识不断提高、基因组学和生物技术的进步以及政府的支持措施和资金。此外，向个人化医疗的转变正在发挥关键作用，人工智慧和机器学习的整合也能提高诊断准确性和决策能力。

主要市场统计
基准年[2023] 26.8亿美元
预计年份 [2024] 31.2亿美元
预测年份 [2030] 82.3亿美元
复合年增长率（%） 17.36%

目前的市场开拓机会在于携带式诊断工具的开发和新兴经济体的市场扩张，这些市场仍有大量未满足的需求。生物技术公司、政府机构和医疗保健提供者之间的策略伙伴关係有助于加速技术的采用。然而，挑战依然存在，包括先进诊断的高成本、监管障碍以及缺乏训练有素的专业人员。市场开拓也受到罕见疾病的异质性和复杂性的限制，这使得标准化诊断通讯协定的发展变得复杂。创新前景包括加强基因检测平台、开发多组体学方法以及利用巨量资料更深入了解疾病机制。

市场本质上是动态的，培养竞争格局需要持续研究、对监管变化做出敏捷响应以及对人才发展的投资。该领域的参与企业必须注重学术界、高科技和医疗产业之间的合作，以促进创新并提高诊断准确性。总体而言，罕见疾病诊断市场对于那些希望克服其复杂性同时改善患者照护的公司来说具有巨大的潜力。

市场动态：揭示快速发展的罕见疾病诊断市场的关键市场洞察

供需的动态交互作用正在改变罕见疾病诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 罕见遗传病患疾病率不断上升，需要早期快速诊断
    • 越来越多地使用翻译和基因组研究来识别新突变
    • 政府在罕见疾病诊断和治疗方面的倡议
  • 市场限制因素
    • 与新的罕见疾病基因检测核准程序相关的严格规定
  • 市场机会
    • 基因技术的进步识别新的罕见疾病基因
    • 罕见遗传疾病诊断的获利投资
  • 市场问题
    • 道德问题和罕见疾病资讯的获取有限

波特五力：驾驭罕见疾病诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解罕见疾病诊断市场的外部影响

外部宏观环境因素在塑造罕见疾病诊断市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解罕见疾病诊断市场的竞争状况

对罕见疾病诊断市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：罕见疾病诊断市场供应商绩效评估

FPNV定位矩阵是评估罕见疾病诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製罕见疾病诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，罕见疾病诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 罕见遗传疾病的增加以及早期快速诊断的需求
      • 越来越多地使用转化研究和基因组监测来识别新突变
      • 政府关于罕见疾病诊断和治疗的倡议
    • 抑制因素
      • 新罕见疾病基因检测核准流程的严格规定
    • 机会
      • 基因技术的进步识别新的罕见疾病基因
      • 罕见遗传疾病诊断的获利投资
    • 任务
      • 道德问题和罕见疾病资讯的获取有限
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 罕见疾病诊断市场：依组成部分

  • 介绍
  • 耗材和检测试剂套件
  • 诊断设备

第七章 罕见疾病诊断市场：依技术分类

  • 介绍
  • 阵列技术
  • 次世代定序
  • 桑格序列

第八章罕见疾病诊断市场：依疾病类型

  • 介绍
  • 癌症
  • 心血管疾病
  • 皮肤科疾病
  • 内分泌/代谢疾病
  • 血液疾病
  • 免疫疾病
  • 肌肉骨骼疾病
  • 神经系统疾病

第九章 罕见疾病诊断市场：依最终用途分类

  • 介绍
  • 诊断实验室
  • 医院/诊所
  • 研究机构和 CRO

第十章 南北美洲罕见疾病诊断药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区罕见疾病诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东、非洲罕见疾病诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 23andMe Inc.
  • 3billion, Inc.
  • Agilent Technologies Inc.
  • ARCHIMED Life Science GmbH
  • ARUP Laboratories
  • AstraZeneca PLC
  • Azenta Life Sciences
  • Baylor Genetics
  • Caris Life Sciences
  • CENTOGENE NV
  • Eurofins Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • In-Depth Genomics
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • MedGenome Labs Ltd
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • Progenity, Inc.
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Travere Therapeutics Inc.
Product Code: MRR-5C6F41F5B034

The Rare Disease Diagnostics Market was valued at USD 2.68 billion in 2023, expected to reach USD 3.12 billion in 2024, and is projected to grow at a CAGR of 17.36%, to USD 8.23 billion by 2030.

The market for rare disease diagnostics is characterized by its critical role in identifying and managing conditions that affect a small percentage of the population. This segment demands advanced technological innovation to improve the accuracy and timeliness of diagnostic processes. The necessity for enhanced diagnostics is underscored by the potential for early intervention and personalized treatment plans that can significantly improve patient outcomes. Applications span genetic testing, biomarker detection, and advanced imaging techniques, with end-use sectors including hospitals, diagnostic laboratories, and research institutions. Key factors driving growth in this market include increasing awareness about rare diseases, advancements in genomics and biotechnology, and supportive government policies and funding. Moreover, the shift towards personalized medicine plays a vital role, as does the integration of AI and machine learning to improve diagnostic accuracy and decision-making.

KEY MARKET STATISTICS
Base Year [2023] USD 2.68 billion
Estimated Year [2024] USD 3.12 billion
Forecast Year [2030] USD 8.23 billion
CAGR (%) 17.36%

Current opportunities lie in developing portable diagnostic tools and expanding the market in emerging economies where there is still significant unmet need. Strategic partnerships between biotech firms, government bodies, and healthcare providers can facilitate accelerated technology adoption. However, challenges persist, including high costs of advanced diagnostics, regulatory hurdles, and a scarcity of trained professionals. Market growth is also constrained by the heterogeneity and complexity of rare diseases, which complicates the development of standardized diagnostic protocols. Innovation prospects include enhancing genetic testing platforms, developing multi-omics approaches, and leveraging big data for deeper insights into disease mechanisms.

The market is inherently dynamic, fostering a competitive landscape where continuous research, agile adaptation to regulatory changes, and investment in talent development are imperative. Players in this sector must focus on collaborations across academia, tech, and healthcare industries to foster innovation and improve diagnostic accuracy. Overall, the rare disease diagnostics market holds significant potential for businesses willing to navigate its complexities while contributing to improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Diagnostics Market

The Rare Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of rare genetic diseases and the need for early & rapid diagnosis
    • Rising use in translational & genomic research for the identification of novel mutations
    • Government initiatives for diagnosis and treatment of rare diseases
  • Market Restraints
    • Stringent regulations associated with the approval process of new rare diseases genetic test
  • Market Opportunities
    • Advancements in genetic technology to Identify new rare disease genes
    • Favorable investments for diagnosis of rare genetic diseases
  • Market Challenges
    • Ethical concerns and access to limited information on rare disease

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Diagnostics Market

A detailed market share analysis in the Rare Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rare Disease Diagnostics Market

A strategic analysis of the Rare Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 23andMe Inc., 3billion, Inc., Agilent Technologies Inc., ARCHIMED Life Science GmbH, ARUP Laboratories, AstraZeneca PLC, Azenta Life Sciences, Baylor Genetics, Caris Life Sciences, CENTOGENE N.V., Eurofins Scientific Inc., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Illumina, Inc., In-Depth Genomics, Invitae Corporation, Laboratory Corporation of America Holdings, MedGenome Labs Ltd, OPKO Health, Inc., PerkinElmer Inc., Progenity, Inc., Quest Diagnostics Incorporated, Sanofi S.A., Thermo Fisher Scientific Inc., and Travere Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Consumable & Assay Kit and Diagnostic Instrument.
  • Based on Technology, market is studied across Array Technology, Next Generation Sequencing, and Sanger Sequencing.
  • Based on Disease Type, market is studied across Cancer, Cardiovascular Disorders, Dermatology Disease, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
  • Based on End-use, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of rare genetic diseases and the need for early & rapid diagnosis
      • 5.1.1.2. Rising use in translational & genomic research for the identification of novel mutations
      • 5.1.1.3. Government initiatives for diagnosis and treatment of rare diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations associated with the approval process of new rare diseases genetic test
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genetic technology to Identify new rare disease genes
      • 5.1.3.2. Favorable investments for diagnosis of rare genetic diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical concerns and access to limited information on rare disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rare Disease Diagnostics Market, by Component

  • 6.1. Introduction
  • 6.2. Consumable & Assay Kit
  • 6.3. Diagnostic Instrument

7. Rare Disease Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Array Technology
  • 7.3. Next Generation Sequencing
  • 7.4. Sanger Sequencing

8. Rare Disease Diagnostics Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Cardiovascular Disorders
  • 8.4. Dermatology Disease
  • 8.5. Endocrine & Metabolism Diseases
  • 8.6. Hematology Diseases
  • 8.7. Immunological Disorders
  • 8.8. Musculoskeletal Disorders
  • 8.9. Neurological Disorders

9. Rare Disease Diagnostics Market, by End-use

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Laboratories & CROs

10. Americas Rare Disease Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Rare Disease Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 23andMe Inc.
  • 2. 3billion, Inc.
  • 3. Agilent Technologies Inc.
  • 4. ARCHIMED Life Science GmbH
  • 5. ARUP Laboratories
  • 6. AstraZeneca PLC
  • 7. Azenta Life Sciences
  • 8. Baylor Genetics
  • 9. Caris Life Sciences
  • 10. CENTOGENE N.V.
  • 11. Eurofins Scientific Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Fulgent Genetics, Inc.
  • 14. Illumina, Inc.
  • 15. In-Depth Genomics
  • 16. Invitae Corporation
  • 17. Laboratory Corporation of America Holdings
  • 18. MedGenome Labs Ltd
  • 19. OPKO Health, Inc.
  • 20. PerkinElmer Inc.
  • 21. Progenity, Inc.
  • 22. Quest Diagnostics Incorporated
  • 23. Sanofi S.A.
  • 24. Thermo Fisher Scientific Inc.
  • 25. Travere Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. RARE DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RARE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RARE DISEASE DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CONSUMABLE & ASSAY KIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC INSTRUMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DERMATOLOGY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023